

STATE OF WEST VIRGINIA



RETIREE HEALTH BENEFIT TRUST FUND

Quarterly Report March 31, 2008

Fiscal Years 2008-2012

November 2008



415 Main Street Reisterstown, MD 21136

Email: info@ccrcactuaries.com

Phone: 410-833-4220 Fax: 410-833-4229

Finance Board West Virginia Retiree Health Benefit Trust Fund State Capitol Complex Building 5, Room 1001 1900 Kanawha Boulevard, East Charleston, WV 25305-0710

Ladies and Gentlemen:

I, Dave Bond, am a Fellow of the Society of Actuaries, a Member of the American Academy of Actuaries, and the Managing Partner in the firm of CCRC Actuaries, LLC ("CCRC Actuaries").

During the 2006 Regular Session of the West Virginia Legislature, House Bill 4654 was enacted creating the West Virginia Retiree Health Benefit Trust Fund ("Trust Fund") for the purpose of providing for and administering retiree post-employment health care benefits, and the respective revenues and costs of those benefits as a cost sharing multiple employer plan. The Public Employees Insurance Agency ("PEIA"), on behalf of the Public Employees Insurance Agency Finance Board ("Board"), is responsible for the day-to-day operation of the Trust Fund, including all administrative functions.

Statutory provisions governing the Trust Fund require the actuary retained by the PEIA to provide technical advice regarding the operation of the Trust Fund. Using the actuarial assumptions most recently adopted by the Board, the actuary is required to develop actuarial valuations of normal cost, actuarial liability, actuarial value of assets, and related actuarial present values for the West Virginia plan for other post-employment benefits including health insurance. Consequently, the Board has requested CCRC Actuaries to prepare a report separating the actuarial projections for the Trust Fund from the PEIA forecast report. The West Virginia Retiree Health Benefit Trust Fund will assume the financial liabilities of the retiree programs currently under the PEIA effective July 1, 2007.

The provisions of the Code of West Virginia ("Code"), 1931, as amended, charge the Board with the responsibility to prepare a proposed financial plan designed to generate revenues sufficient to meet all estimated program and administrative costs of the PEIA, including incurred but unreported claims, for the fiscal year for which the plan is proposed. CCRC Actuaries has been retained by the PEIA to review the proposed financial plan, and as supported by our work, to render an opinion stating whether the plan may be reasonably expected to generate sufficient revenues to meet estimated insurance program and administrative costs of the plan through FY 2012. The analysis is to be prepared on an accrued and incurred reporting basis for a projection period not to exceed five years.

The Code provisions also require the Board to establish and maintain a reserve fund for PEIA for the purposes of offsetting unanticipated claim losses in any fiscal year. Beginning with the Fiscal Year 2002 plan and for each succeeding fiscal year plan, the Board shall transfer ten percent of the projected total plan costs for that year into the reserve fund, which is to be certified by the actuary and included in the final, approved financial plan submitted to the Governor and Legislature in accordance with the provisions of the Code. Any moneys saved in a plan year shall be transferred into the reserve fund. At the close of any fiscal year in which the balance in the reserve fund exceeds the recommended reserve amount by fifteen percent, these excess funds shall be transferred to the West Virginia Retiree Health Benefit Trust Fund. Additionally, during the 2007 Regular Session, the West Virginia Legislature enacted House Bill 2007 ("HB 2007") requiring an appropriation of \$39,674,000 to the Other Post Employment Benefit ("OPEB") Contribution Accumulation Fund in FY 2008. It should be noted that \$30,730,000 from the General Revenue Fund and \$46,600,000 from the Excess Lottery Revenue Fund will be transferred to the OPEB Contribution Accumulation Fund in FY 2009. A transfer from the Debt Reduction Fund Revenue is assumed into the OPEB Contribution Accumulation Fund in FY 2009.

In accordance with the Code provisions, in FY 2008, PEIA is projected to transfer excess reserves to the Trust Fund in the amount of \$27,679,595 and \$80,487,422 for FY 2006 and FY 2007, respectively.

CCRC Actuaries has provided preliminary forecasts for the Trust Fund for fiscal years ending June 30, 2008 ("FY 2008"), June 30, 2009 ("FY 2009"), June 30, 2010 ("FY 2010"), June 30, 2011 ("FY 2011"), and June 30, 2012 ("FY 2012"). This opinion of plan adequacy is based on the projections through FY 2012 using updated future revenue and plan modifications provided by the Board in the plan adopted in December 2007.

Effective July 1, 2007, PEIA has contracted with Coventry Advantra Freedom to provide Medicare Advantage/Prescription Drug Plan ("MAPD") Benefits to Medicare-eligible retired employees and dependents. Under this arrangement, Coventry Advantra Freedom has assumed the financial risk of providing comprehensive medical and prescription drug coverage with limited copayments. Accordingly, this report assumes that the Trust Fund will not continue to participate in the Retiree Drug Subsidy ("RDS") program under CMS Medicare Part D, the enactment of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, after Fiscal Year 2007.

Current Medicare coverages were transferred from a self-insured secondary basis by PEIA to MAPD. However, it should be noted that new Medicare eligible retirees, who become Medicare eligible between July 1, 2007 and June 30, 2008, will be covered on a secondary basis by the PPB Plan until July 1, 2008, at which time they will be covered under the MAPD. For the purposes of these projections we have assumed that the MAPD remains in effect throughout the forecast. In addition to newly eligible Medicare retirees, PEIA will continue to provide coverage under the original self-insured secondary basis for those Medicare retirees with access issues to the Coventry Advantra Freedom program.

The Medicaid / PEIA Hospital Bill ("Bill") has been extended and is anticipated to continue to provide PEIA with hospital charge savings through discounts for all retiree non-Medicare coverages. These hospital savings are assumed to increase by the medical trend assumptions in Fiscal Year 2008 and subsequently. We are assuming that the Bill will continue throughout the forecast and PEIA will not receive any future direct transfers in lieu of the savings resulting from the Bill.

In reviewing the plan, CCRC Actuaries utilized information concerning the plan's prior experience, covered individuals, plan revenues, plan benefits, plan administrative costs, and other expenses. This information was developed and provided by PEIA, the plan's third party administrators and other sources. In our review, we completely relied on the accuracy of this information and did not perform any due diligence on the information.

Since the adoption of the financial plan in December 2007, PEIA has experienced favorable claim expense. In the circumstances, and subject to the conditions described herein, based on our review, we believe the financial plan approved by the Board for FY 2008 through FY 2012 may be reasonably expected to generate sufficient revenues, when combined with the existing surplus, to meet estimated insurance program and administrative costs of the Trust Fund.

This conclusion is based on significant revenue increases in employer and employee premiums in later fiscal years of the plan through FY 2012 as approved by the Board in December 2007.

The preparation of any estimate of future health costs requires consideration of a broad array of complex social and economic events. Changes in reimbursement methodology, the emergence of new and expensive medical procedures and prescription drugs options, and the continuing evolution and changes of the framework of MAPD and other managed care options impacting Non-Medicare retirees, as are contemplated in the Board's proposed plan, increase the level of uncertainty of such estimates. As such, the estimate costs of insurance program contain considerable uncertainty and variability and actual experience may not conform to the assumptions utilized in this report.

Respectfully,

Dave Bond

Dave Bond, F.S.A., M.A.A.A. Managing Partner

Brad Paulin

Bradley Paulis Reviewing Partner

West Virginia Retiree Health Benefit Trust Fund Report of Independent Actuary Financial Plan for FY 2008 – FY 2012

OVERVIEW

This report analyzes revenues and expenses related to funding the health insurance benefits of retired employees of the State of West Virginia and various local agencies, together with their dependents. This report is intended for the sole use of the Board, and any other use requires written approval by CCRC Actuaries.

This report was compiled utilizing claims data collected by PEIA's third party administrators through June 2008 for prescription drugs and medical claims. Enrollment data, administrative expenses, managed care capitations, and plan revenues were provided at special request from PEIA. Revenue assumptions are based on premium rates, assumed interest income and significant general and special revenue allocations provided by the Governor, some which have not been approved by the West Virginia Legislature. In addition, other information became available through presentations made at Board meetings, which has been used in arriving at our conclusions.

The Code of West Virginia establishes the actuarial reporting requirements for the Trust Fund on an incurred basis for medical claims and capitations and on an accrued basis for administrative expenses and revenue for a period not to exceed five years. At the request of the Board, the reporting basis is based upon the Trust Fund. The Trust Fund represents all state and local agency retirees and their survivors. The Trust Fund has been allocated the anticipated administrative costs incurred by PEIA for retiree coverages.

KEY ASSUMPTIONS

A. Enrollment Changes

The Board has requested that the projection assume retiree enrollment growth consistent with the experience of the plan. These projections assume that the Trust Fund will annually have 1,000 additional retirees. While we have recently observed a net increase of 1,018 retirees from June 2006 to June 2007, we note that from June 2005 through June 2007, the average annual increase in retirees was 1,006, approximating our current assumption. It should be noted that PEIA had recently changed the new enrollment system after March 2008 and only limited enrollment information is available at this time. CCRC Actuaries has only updated the claims analysis based on the prorated enrollment through June 2008.

In aggregate, March 2008 enrollment has decreased by 422 coverages since the end of FY 2007. Aggregate Preferred Provider Benefit ("PPB") enrollment has decreased by 419 in total over the same period, while managed care enrollment continues to cover fewer participants, with a slight decrease of 3 coverages.

The following chart summarizes the current enrollment as of the selected monthly billing dates of June 2006, June 2007 and March 2008 for purposes of comparison:

Trust Fund		Preferred Provider Benefit			Managed Care			
	Coverage	Jun-06	Jun-07	Mar-08	Jun-06	Jun-07	Mar-08	
Retirees	Medicare Single	16,007	16,273	15,584	-	-	-	
	Medicare Family	9,385	9,636	9,623	_	_	_	
	Medicare Total	25,392	25,909	25,207	-	-	-	
	Non Medicare Single	2,914	3,120	3,191	191	214	214	
	Non Medicare Family	4,234	4,491	4,703	181	196	193	
	Non Medicare Total	7,148	7,611	7,894	372	410	407	
	Retiree Total	32,540	33,520	33,101	372	410	407	
	Grand Total				32,912	33,930	33,508	

B. Changes in Claim Backlog

Detail of the medical claim backlog is presented in the PEIA report titled "PEIA Quarterly Report March 31, 2008".

C. Trend Analysis

CCRC Actuaries performed the detailed medical and prescription drugs trend analysis in the report titled, "Medical & Prescription Drugs Claims Trend Report - October 2007". This report includes the detailed trend analysis in aggregate for both PEIA and Trust Fund experience by medical and prescription drugs category and whether the PEIA, the Trust Fund or Medicare was primary. Based on the analysis, we have retained the FY 2008 Non-Medicare medical claim trend to 6.0%, and the FY 2008 Medicare medical claim trend at 6.0%. Based on Trust Fund's favorable prescription drug experience, we have retained our trend assumption for all prescription drugs coverage at 12.0% in FY 2008.

The current projection assumes the trends on the following table:

Claim Type	Previous Assumption	Current Assumption		
	FY 2008 Trend	FY 2008 Trend		
Non-Medicare – Medical	6.0%	6.0%		
Medicare – Medical	6.0%	6.0%		
Non-Medicare – Drugs	12.0%	12.0%		
Medicare – Drugs	12.0%	12.0%		

In addition, we have assumed that trends will increase by 0.5% in each successive fiscal year beginning in FY 2009. At the Board's request, the baseline trend assumptions have been established to reflect the most likely or expected trends. In order to provide information on the impact of varying trend assumptions, two alternative trend scenarios were developed. The Optimistic Scenario incorporates trend assumptions 2.0% below the Baseline Scenario and the Pessimistic Scenario incorporates trend assumptions 2.0% above the Baseline Scenario.

The following chart summarizes the trend results observed for the plan using data through June 2008. It is important to note that these trends <u>have not</u> been adjusted to reflect savings as a result of the expansion of the drug rebate program or the claim savings due to changes in provider reimbursement methodologies nor changes in the benefit structure. In developing the claim cost projection, we have reflected for benefit and reimbursement changes as an adjustment to the gross trend assumption.

Aggregate Trust Fund Historical Trends (Retirees)

Fiscal	Non-Medicare	Medicare	Non-Medicare	Medicare	
Year	Medical	Medical	Drugs	Drugs	<u>Total</u>
2003	-18%	3%	0%	11%	0%
2004	0%	10%	-2%	3%	5%
2005	-2%	6%	1%	16%	8%
2006	5%	6%	17%	11%	9%
2007	1%	6%	5%	6%	5%
2008	11%	N/A	-9%	N/A	N/A

PEIA has contracted with Coventry Advantra Freedom to provide MAPD Benefits to Medicare-eligible retired employees and dependents. Under this arrangement, Coventry Advantra Freedom has assumed the financial risk of providing comprehensive medical and prescription drug coverage with limited copayments. As a result, Fiscal Year 2008 Medicare trends are non-credible.

D. Enrollment, Claim, Expense and Revenue Assumptions

Using aggregate Trust Fund paid claim data through June 2008 for medical claims and for prescription drugs claims, average annualized incurred unit claim costs were developed for the Trust Fund for both self-funded and managed care coverages. CCRC Actuaries has developed the claim cost on an adjusted exposure basis using the respective expected claim cost for each coverage type. The adjusted exposure methodology weighs the expected claim cost under each coverage type for single, member and children, and family coverages based on observed differences in health care cost. For example, under this methodology single coverage types are given a weight of 1.0 exposure, whereas member and children coverages are given a greater weighting based on historical expected health care cost relationships. Based on this methodology, the projection of FY 2008 claims and expenses are summarized in the following charts. It should be noted that the chart reflects per policy information. It should be noted that PEIA had recently changed the new enrollment system after March 2008, and we are showing the adjusted exposure through March 2008 below.

Fiscal Yea	Fiscal Year 2008 Projection		Revenue			Expenses					
			Month	ly]	Monthly	Mo	onthly	Μ	lonthly	N	Aonthly
			Employ	er E	mployee	Μ	edical		Drugs	Ca	pitation
Fund	Program	Policies	Premiun	ns Pi	remiums		Costs		Costs		Costs
Retiree	Medicare Coventry Advantra Freedom <u>Non-Medicare</u>	25,234 7,936				\$	496	\$	213	\$	135
	Total Non-Medicare <u>Managed Care</u>	33,170 408	\$ - \$ -	\$ \$	142 499					\$	1,943
	Total	33,578									

Projected plan revenues and administrative expenses were provided by PEIA. The following chart summarizes the additional revenues from retirees, Medicare Part D reimbursements and Mandatory Transfer From General Revenue under the West Virginia Legislature enacted House Bill 2007.

	Fiscal Year	Fiscal Year	Fiscal Year	Fiscal Year	Fiscal Year
Source	2008	2009	2010	2011	2012
Additional Retiree					
Premiums	(\$9,200,000)	\$0	\$6,700,000	\$10,900,000	\$11,100,000
Medicare Part D					
Revenue	\$0	\$0	\$0	\$0	\$0
Debt Reduction Fund	\$5,800,000	\$13,700,000	\$13,700,000	\$13,700,000	\$13,700,000
Mandatory Transfer					
From General Revenue	\$39,674,000	\$77,330,000	\$0	\$0	\$0

Board Decisions – December 2007

Future fiscal year State revenue increases will require legislative appropriation. Additional retiree premiums represent premiums paid by retirees either directly or through sick and annual leave conversion credits.

Additionally, PEIA management has assumed that the Retiree Premium Assistance Program will grow as a direct result from the required retiree premium increases in the financial plan. The program's cost is currently projected to grow from approximately \$2.1 million in FY 2008 to approximately \$2.9 million in FY 2012, based on the Board's direction and projected retiree enrollment growth in the financial plan.

E. <u>Provider Reimbursement Changes</u>

Effective July 1, 2007, PEIA has contracted with Coventry Advantra Freedom to provide Medicare Advantage/Prescription Drug Plan ("MAPD") Benefits to Medicare-eligible retired employees and dependents. Under this arrangement, Coventry Advantra Freedom has assumed the financial risk of providing comprehensive medical and prescription drug coverage with limited copayments. Accordingly, this report assumes that the Trust Fund will not continue to participate in the Retiree Drug Subsidy ("RDS") program under CMS Medicare Part D, the enactment of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, after Fiscal Year 2007.

FISCAL YEAR 2008 FORECAST

The financial forecast for FY 2008 under the Baseline scenario is presented in the Appendix. The Baseline forecast for FY 2008, projects accrued revenue of \$386,446,142 and incurred plan expenses of \$149,722,202 to produce a fiscal year surplus of \$236,723,940.

FISCAL YEAR 2009 FORECAST

The financial forecast for FY 2009 under the Baseline scenario is presented in the Appendix. The Baseline forecast for FY 2009, projects accrued revenue of \$311,975,373 and incurred plan expenses of \$185,623,519 to produce a fiscal year surplus of \$126,351,854.

FISCAL YEAR 2010 FORECAST

The financial forecast for FY 2010 under the Baseline scenario is presented in the Appendix. The Baseline forecast for FY 2010, projects accrued revenue of \$263,083,951 and incurred plan expenses of \$211,061,919 to produce a fiscal year surplus of \$52,022,032.

FISCAL YEAR 2011 FORECAST

The financial forecast for FY 2011 under the Baseline scenario is presented in the Appendix. The Baseline forecast for FY 2011, projects accrued revenue of \$293,706,811 and incurred plan expenses of \$240,053,767 to produce a fiscal year surplus of \$53,653,044.

FISCAL YEAR 2012 FORECAST

The financial forecast for FY 2012 under the Baseline scenario is presented in the Appendix. The Baseline forecast for FY 2012, projects accrued revenue of \$328,164,718 and incurred plan expenses of \$273,187,620 to produce a fiscal year surplus of \$54,977,098.

LITIGATION

The forecasts presented in the attached tables do not contemplate any additional revenues or expenses to be generated from litigation activities.

SUMMARY

It should be noted that the aggregate PEIA and Trust Fund reserves will meet or exceed the 10% of program expense requirement under the Baseline Scenario assumptions. With projected changes to the plan as adopted in the Board, we are forecasting that the plan will meet the 10% reserve target through the projection period ending with the Fiscal Year 2012. These projections are based on significant MAPD savings effective in FY 2008 and significant revenue increases projected by PEIA and are contingent on legislative approval. These forecasts are based on assumptions including the estimated cost and savings of plan changes, expected trend levels and exposure levels. The continued enrollment changes of the managed care options, changes in physician, ambulatory and hospital provider reimbursement; possible changes in methodology of managed care premium calculation; and changes in the prescription drugs program, can be expected to further exacerbate the difficulty of projecting future medical and drugs claim levels and lags. These projections do not incorporate any anticipated effects of national or state health care reform, such as Medicare and Medicaid reform. On the national level, it would not be surprising to see significant changes in the MAPD program, which will impact Trust Fund financial projections. As such, actual results deviating from those amounts projected in these pages should not be unexpected. With the legislatively mandated requirement of a five-year projection, it should be assumed that constant modifications would be required.

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2008

PERIOD 7/1/2007 - 6/30/2008

	TRUST Total
Revenues Local Agencies - Pay Go Premiums State Agencies Employers - Pay Go Premiums State Agencies Employees - Pay Go Premiums Retiree Premiums - PPB Retiree Premiums - MCO Local Agencies - Initial UAAL OPEB Funding State Agencies - Initial UAAL OPEB Funding Debt Reduction Fund Mandatory Transfer from General Revenue PEIA Mandatory Transfer to WV RHBT 2007 PEIA Mandatory Transfer to WV RHBT 2006 Non Par Premiums Investment Incomp	\$ 17,254,370 91,527,844 21,625,749 56,496,298 2,445,194 4,761,728 34,000,000 5,800,000 39,674,000 80,487,422 27,679,595 3,715,594
Investment Income Total Revenue	\$ 978,348 386,446,142
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Medicare Medical Claims Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations MAPD Capitations Administration Retiree Assistance Program Director's Discretionary Fund Total Expenses	\$ 47,233,373 20,300,044 1,147,151 1,832,656 9,514,573 58,320,000 9,181,463 2,117,772 75,170 149,722,202
Fiscal Year Results	\$ 236,723,940
Beginning Plan Reserve	3,166,951
Ending Plan Reserve	\$ 239,890,891

KEY ASSUMPTIONS						
Pay Go Monthly Premium	\$	151.08	Claim and O			
Additional Retiree Premiums	\$	(9,200,000)	<u>Eligibility</u>	Medical	Drugs	
			Non-Medicare	6.0%	12.0%	
			Medicare	6.0%	12.0%	
			Capitations		5.0%	
			Administrative Expense		5.0%	
Number of Net New Retirees		1,000	Pay Go Monthly Premium		10.0%	

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2009

PERIOD 7/1/2008 - 6/30/2009

	TRUST Total
RevenuesLocal Agencies - Pay Go PremiumsState Agencies Employers - Pay Go PremiumsState Agencies Employees - Pay Go PremiumsRetiree Premiums - PPBRetiree Premiums - MCOLocal Agencies - Initial UAAL OPEB FundingState Agencies - Initial UAAL OPEB FundingDebt Reduction FundMandatory Transfer from General RevenueMandatory Transfer from Excess LotteryPEIA Mandatory Transfer to WV RHBT 2008Non Par PremiumsInvestment Income	\$ 18,979,808 100,620,471 23,848,481 57,919,887 2,510,516 - 13,700,000 30,730,000 46,600,000 - 4,161,465 12,904,745
Total Revenue	\$ 311,975,373
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Medicare Medical Claims Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations MAPD Capitations Administration Retiree Assistance Program Director's Discretionary Fund Total Expenses	\$ 53,706,103 24,509,818 1,219,363 2,058,019 9,966,030 81,919,177 9,640,536 2,287,194 317,279 185,623,519
Fiscal Year Results	\$ 126,351,854
Beginning Plan Reserve	239,890,891
Ending Plan Reserve	\$ 366,242,745

KEY ASSUMPTIONS

Pay Go Monthly Premium	\$ 166.19	Claim and O	ther Expense Trends	
Additional Retiree Premiums	\$ -	<u>Eligibility</u>	Medical	Drugs
		Non-Medicare	6.5%	12.5%
		Medicare	6.5%	12.5%
		Capitations		30.0%
		Administrative Expense		5.0%
Number of Net New Retirees	1,000	Pay Go Monthly Premium		10.0%

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2010

PERIOD 7/1/2009 - 6/30/2010

	TRUST Total
Revenues Local Agencies - Pay Go Premiums State Agencies Employers - Pay Go Premiums State Agencies Employees - Pay Go Premiums Retiree Premiums - PPB Retiree Premiums - MCO Local Agencies - Initial UAAL OPEB Funding State Agencies - Initial UAAL OPEB Funding Debt Reduction Fund Mandatory Transfer from General Revenue Mandatory Transfer to WV RHBT 2009 Non Par Premiums Investment Income	\$ 20,877,788 110,197,720 26,718,127 64,798,351 2,808,666 - - 13,700,000 - - 4,660,840 19,322,459
Total Revenue	\$ 263,083,951
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Medicare Medical Claims Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations MAPD Capitations Administration Retiree Assistance Program Director's Discretionary Fund Total Expenses	\$ 61,128,700 29,600,408 1,302,219 2,321,389 10,763,313 93,017,111 10,122,563 2,470,169 336,047 211,061,919
Fiscal Year Results	\$ 52,022,032
Beginning Plan Reserve	366,242,745
Ending Plan Reserve	\$ 418,264,777

KEY ASSUMPTIONS						
Pay Go Monthly Premium	\$	182.81	Claim and Other Expense Trends			
Additional Retiree Premiums	\$	6,700,000	Eligibility	Medical	Drugs	
			Non-Medicare	7.0%	13.0%	
			Medicare	7.0%	13.0%	
			Capitations		8.0%	
			Administrative Expense		5.0%	
Number of Net New Retirees		1,000	Pay Go Monthly Premium		10.0%	

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2011

PERIOD 7/1/2010 - 6/30/2011

		TRUST Total
Revenues Local Agencies - Pay Go Premiums State Agencies Employers - Pay Go Premiums State Agencies Employees - Pay Go Premiums Retiree Premiums - PPB Retiree Premiums - MCO Local Agencies - Initial UAAL OPEB Funding State Agencies - Initial UAAL OPEB Funding Debt Reduction Fund Mandatory Transfer from General Revenue Mandatory Transfer to WV RHBT 2010 Non Par Premiums Investment Income	\$	22,965,567 121,131,541 29,475,891 75,889,549 3,289,426 - - 13,700,000 - - 5,220,141 22,034,696
Total Revenue	\$	22,034,090
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Medicare Medical Claims Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations MAPD Capitations Administration Retiree Assistance Program Director's Discretionary Fund Total Expenses	\$ \$	69,635,106 35,749,519 1,397,219 2,630,074 11,624,378 105,366,432 10,628,691 2,667,783 354,565 240,053,767
Fiscal Year Results	\$	53,653,044
Beginning Plan Reserve Ending Plan Reserve	\$	418,264,777 471,917,822

KEY ASSUMPTIONS											
Pay Go Monthly Premium	\$	201.09	Claim and C	Other Expense Trends							
Additional Retiree Premiums	\$	10,900,000	<u>Eligibility</u>	Medical	Drugs						
			Non-Medicare	7.5%	13.5%						
			Medicare	7.5%	13.5%						
			Capitations		8.0%						
			Administrative Expense		5.0%						
Number of Net New Retirees		1,000	Pay Go Monthly Premium		10.0%						

WEST VIRGINIA RETIREE HEALTH BENEFIT TRUST FINANCIAL FORECAST FISCAL YEAR 2012

PERIOD 7/1/2011 - 6/30/2012

	TRUST Total
Revenues Local Agencies - Pay Go Premiums State Agencies Employers - Pay Go Premiums State Agencies Employees - Pay Go Premiums Retiree Premiums - PPB Retiree Premiums - MCO Local Agencies - Initial UAAL OPEB Funding State Agencies - Initial UAAL OPEB Funding Debt Reduction Fund Mandatory Transfer from General Revenue Mandatory Transfer to WV RHBT 2011 Non Par Premiums Investment Income	\$ 25,262,124 133,167,811 32,500,364 88,989,878 3,857,274 - - 13,700,000 - - 5,846,558 24,840,709
Total Revenue	\$ 24,840,709 328,164,718
Program Expenses Non-Medicare Medical Claims Non-Medicare Prescription Drug Claims Medicare Medical Claims Medicare Prescription Drug Claims Non-Medicare Managed Care Capitations MAPD Capitations Administration Retiree Assistance Program Director's Discretionary Fund Total Expenses	\$ 79,424,160 43,199,529 1,506,138 2,992,962 12,554,328 119,096,334 11,160,126 2,881,205 372,838 273,187,620
Fiscal Year Results	\$ 54,977,098
Beginning Plan Reserve	471,917,822
Ending Plan Reserve	\$ 526,894,919

KEY ASSUMPTIONS											
Pay Go Monthly Premium	\$	221.20	Claim and O	ther Expense Trends							
Additional Retiree Premiums	\$	12,900,000	<u>Eligibility</u>	Medical	Drugs						
			Non-Medicare	8.0%	14.0%						
			Medicare	8.0%	14.0%						
			Capitations		8.0%						
			Administrative Expense		5.0%						
Number of Net New Retirees		1,000	Pay Go Monthly Premium		10.0%						

					Fiscal Ye	ar 2004						
Exposure						2004						
	Jul-03	Aug-03	Sep-03	Oct-03	Nov-03	Dec-03	Jan-04	Feb-04	Mar-04	Apr-04	May-04	Jun-04
NonMed_NonDrug	12,281	12,519	12,636	11,939	11,800	13,119	13,132	13,089	13,172	13,171	13,569	13,366
Med NonDrug	29,617	29,510	29,369	29,825	29,932	30,087	30,146	30,193	30,217	30,197	31,151	30,560
NonMed_Drug	11,388	11,611	11,722	11,073	10,941	12,155	12,168	12,129	12,203	12,202	12,572	12,382
Med_Drug	30,795	30,683	30,536	31,014	31,125	31,287	31,350	31,400	31,424	31,401	32,398	31,785
	<u>Jul-03</u>	<u>Aug-03</u>	<u>Sep-03</u>	<u>Oct-03</u>	<u>Nov-03</u>	<u>Dec-03</u>	<u>Jan-04</u>	<u>Feb-04</u>	<u>Mar-04</u>	<u> Apr-04</u>	<u>May-04</u>	<u>Jun-04</u>
NonMed_NonDrug	\$175.84	\$165.40	\$208.39	\$253.85	\$199.27	\$217.17	\$213.86	\$215.01	\$241.38	\$187.46	\$210.29	\$222.55
Med_NonDrug	96.46	94.43	102.25	106.45	92.90	100.40	137.17	113.01	129.09	116.90	107.12	113.57
NonMed_Drug	56.39	76.22	81.46	93.40	86.51	115.68	85.05	81.85	90.92	87.63	77.21	81.84
Med_Drug	<u>80.56</u>	<u>136.99</u>	<u>115.91</u>	<u>154.85</u>	<u>141.87</u>	<u>206.25</u>	<u>156.84</u>	<u>145.44</u>	<u>165.67</u>	<u>160.01</u>	<u>138.69</u>	<u>97.30</u>
Total	\$409.25	\$473.04	\$508.02	\$608.54	\$520.54	\$639.49	\$592.92	\$555.31	\$627.05	\$552.00	\$533.31	\$515.26
Change From Prior	Year - Mont	h to Month	Analysis									
NonMed_NonDrug	6.5%	-12.1%	10.6%	15.2%	-11.0%	23.8%	-13.0%	7.7%	1.1%	3.0%	-15.1%	-1.4%
Med_NonDrug	5.7%	4.4%	14.0%	11.1%	2.7%	11.1%	13.3%	19.3%	17.0%	12.6%	-0.2%	10.7%
NonMed_Drug	-4.3%	-10.1%	-2.5%	2.8%	0.7%	26.4%	-6.1%	2.4%	1.3%	9.8%	-19.4%	-17.8%
Med_Drug	<u>-14.0%</u>	<u>4.8%</u>	<u>-10.8%</u>	<u>10.4%</u>	<u>5.0%</u>	<u>40.5%</u>	<u>8.3%</u>	<u>10.9%</u>	<u>14.7%</u>	<u>15.5%</u>	<u>-10.2%</u>	<u>-39.2%</u>
Total	0.0%	-4.3%	3.3%	11.2%	-2.8%	26.8%	-1.5%	9.9%	7.5%	9.5%	-11.9%	-12.3%
Change From Prior	Year - Quart	ter to Quart										
NonMed_NonDrug			1.5%			8.2%			-2.0%			-5.4%
Med_NonDrug			8.0%			8.3%			16.3%			7.6%
NonMed_Drug			-5.8%			10.2%			-0.9%			-10.3%
Med_Drug			<u>-5.9%</u>			<u>19.1%</u>			<u>11.3%</u>			<u>-12.6%</u>
Total			-0.3%			11.5%			5.0%			-5.7%
Change From Prior	Year - Year	to Year Ana	•									
NonMed_NonDrug			-11.2%			-5.0%			-2.2%			0.4%
Med_NonDrug			4.1%			6.7%			10.7%			10.3%
NonMed_Drug			-2.2%			0.2%			0.1%			-1.6%
Med_Drug			<u>5.9%</u>			<u>7.7%</u>			<u>8.5%</u>			<u>3.1%</u>
Total			-3.1%			1.0%			3.2%			2.6%

					Fiscal Ye	or 2005]
Exposure					riscai It	ai 2005						
	Jul-04	Aug-04	Sep-04	Oct-04	Nov-04	Dec-04	Jan-05	Feb-05	Mar-05	Apr-05	May-05	Jun-05
NonMed_NonDrug	13,923	14,586	14,603	14,608	14,677	14,699	14,636	14,677	14,667	14,523	14,444	14,416
Med_NonDrug	30,671	30,821	30,934	31,117	31,106	31,109	31,241	31,264	31,267	31,401	31,412	31,457
NonMed_Drug	12,897	13,506	13,523	13,527	13,592	13,612	13,553	13,591	13,585	13,451	13,376	13,353
Med_Drug	31,901	32,058	32,175	32,367	32,356	32,361	32,500	32,524	32,527	32,679	32,690	32,739
	<u>Jul-04</u>	Aug-04	<u>Sep-04</u>	<u>Oct-04</u>	<u>Nov-04</u>	Dec-04	<u>Jan-05</u>	Feb-05	<u>Mar-05</u>	<u>Apr-05</u>	<u>May-05</u>	<u>Jun-05</u>
NonMed_NonDrug	\$176.59	\$185.92	\$192.00	\$180.48	\$192.01	\$183.80	\$217.27	\$215.91	\$241.21	\$206.40	\$218.30	\$255.56
Med_NonDrug	101.19	106.39	106.92	105.83	104.05	102.13	143.24	125.42	131.58	121.93	121.32	120.07
NonMed_Drug	70.13	77.09	94.73	71.40	90.87	102.08	93.88	87.98	78.57	72.18	92.83	90.00
Med_Drug	<u>107.55</u>	<u>143.58</u>	<u>180.98</u>	<u>136.83</u>	<u>167.95</u>	<u>187.16</u>	<u>169.71</u>	<u>157.75</u>	<u>181.65</u>	<u>174.18</u>	<u>180.00</u>	<u>187.05</u>
Total	\$455.46	\$512.97	\$574.64	\$494.54	\$554.89	\$575.16	\$624.10	\$587.06	\$633.01	\$574.69	\$612.46	\$652.69
Change From Prior Y	rear - Mont	h to Month	Analysis									
NonMed_NonDrug	0.4%	12.4%	-7.9%	-28.9%	-3.6%	-15.4%	1.6%	0.4%	-0.1%	10.1%	3.8%	14.8%
Med_NonDrug	4.9%	12.7%	4.6%	-0.6%	12.0%	1.7%	4.4%	11.0%	1.9%	4.3%	13.2%	5.7%
NonMed_Drug	24.4%	1.1%	16.3%	-23.5%	5.0%	-11.8%	10.4%	7.5%	-13.6%	-17.6%	20.2%	10.0%
Med_Drug	<u>33.5%</u>	<u>4.8%</u>	<u>56.1%</u>	<u>-11.6%</u>	<u>18.4%</u>	<u>-9.3%</u>	<u>8.2%</u>	<u>8.5%</u>	<u>9.6%</u>	<u>8.9%</u>	<u>29.8%</u>	<u>92.2%</u>
Total	11.3%	8.4%	13.1%	-18.7%	6.6%	-10.1%	5.3%	5.7%	0.9%	4.1%	14.8%	26.7%
Change From Prior Y	Year - Quart	ter to Quart	er Analysis									
NonMed_NonDrug			0.9%			-17.0%			0.6%			9.7%
Med_NonDrug			7.3%			4.1%			5.5%			7.6%
NonMed_Drug			13.0%			-10.6%			1.0%			3.4%
Med_Drug			<u>29.6%</u>			<u>-2.2%</u>			<u>8.8%</u>			<u>36.7%</u>
Total			11.0%			-8.1%			3.9%			14.9%
Change From Prior Y	Year - Year	to Year Ana	alysis									
NonMed_NonDrug			0.3%			-6.2%			-5.5%			-1.8%
Med_NonDrug			10.0%			9.0%			6.1%			6.1%
NonMed_Drug			2.4%			-3.3%			-2.8%			0.7%
Med_Drug			<u>10.4%</u>			<u>4.6%</u>			<u>4.1%</u>			<u>16.1%</u>
Total			5.1%			-0.1%			-0.3%			4.8%

Fiscal Year 2006 Exposure Jul-05 Aug-05 Sep-05 Oct-05 Is.549 Jan-06 Feb-06 Mar-06 Apr-06 Mar-06 Jun-06 NonMed_NonDrug 14.864 15.501 15.616 15.455 15.454 15.638 15.382 15.352 15.353 15.358 15.353 15.358 15.352 15.353 15.358 15.358 15.352 15.358 15.352 15.358 15.358 15.358 15.358 15.358 15.358 15.358 15.358 15.358 15.358 15.358 15.358 15.358 15.358 15.358 15.358 15.358 15.358 14.229 33.491 33.491 33.491 33.491 33.491 33.463 Med_Drug 101-05 Aug-05 Sep-05 Oct-05 Jan-06 Feb-06 Mar-06 Apr-06						Eisoal V	or 2006						1
Jul-05 Aug-05 Sep-05 Oct-05 Now-05 Dec-05 Jan-06 Feb-06 Mar-05 Apr-06 Mar-05 Jan-06 Feb-06 Mar-05 Mar-05 Jan-06 Feb-06 Mar-05 Mar-05 Mar-05 Jan-06 Feb-06 Mar-05 Jan-06 Feb-06<	Exposuro					FISCAL TE	ear 2006						
NonMed_NonDrug 14,864 15,500 15,616 15,455 15,454 15,534 15,588 15,382 15,387 15,387 15,387 15,387 15,387 15,387 15,387 15,387 15,387 15,387 15,387 15,387 15,387 15,387 15,387 15,387 15,387 15,387 15,381 14,340 14,321 14,114 14,389 14,353 14,544 14,420 14,229 Med_Drug 32,828 32,961 33,067 33,204 33,275 33,350 33,360 33,393 33,422 33,491 33,497 33,463 Med_Drug 102.95 Aug-05 Sep-05 Oct-05 Mov-05 Sel 0.95 Sel 0.92 Sel 0.92 Sel 0.92 Sel 0.91 Sel 0.92 Sel 0.92 Sel 0.91 Sel 0.92 Sel 0.92 Sel 0.91 Sel 0.92 Sel 0.92 Sel 0.92 Sel 0.91 Sel 0.92 Sel 0.91 Sel 0.91 Sel	Exposure	1.1.05	Aug. 05	Son 05	Oct 05	Nov 05	Doc. 05	lan 06	Eab 06	Mar 06	Apr 06	May 06	lun 06
Med_NonDrug 31,544 31,669 31,771 31,901 31,968 32,040 32,050 32,017 32,174 32,183 32,149 NonMed_Drug 13,767 14,356 14,463 14,312 14,314 14,389 14,353 14,534 14,440 14,228 14,226 14,229 Med_Drug 32,828 32,961 33,067 33,204 33,275 33,350 33,360 33,393 33,342 33,491 33,463 NonMed_NonDrug \$179.38 \$264.65 \$196.24 \$213.57 \$198.48 \$210.00 \$210.92 \$219.18 \$240.33 \$218.03 \$218.03 Med_NonDrug 102.95 116.37 111.76 117.94 113.97 109.65 156.44 125.70 138.21 123.43 128.20 123.43 NonMed_Drug 164.48 95.14 94.71 198.01 101.71 106.08 102.84 198.06 118.77 128.64 115.11 119.44 Med_Drug 128.47 175.04 198.01 181.77 202.84 204.50 204.50 566.31 566.31	NonMod NonDrug												
NonMed_Drug 13,767 14,366 14,463 14,312 14,344 14,389 14,353 14,534 14,440 14,248 14,226 14,229 Med_Drug 32,828 32,961 33,067 33,204 33,275 33,360 33,360 33,393 33,422 33,491 33,497 33,463 NonMed_NonDrug \$179.38 \$264.65 \$196.24 \$213.57 \$198.48 \$210.00 \$210.92 \$219.18 \$240.92 \$197.54 \$246.33 \$218.03 Med_NonDrug 102.95 116.37 111.76 117.94 113.97 109.65 156.44 125.70 138.21 123.43 128.20 123.43 128.20 123.43 128.20 123.43 128.20 123.43 128.20 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.92 \$210.93 \$210.93 \$210.93		,											
Med_Drug 32,828 32,961 33,067 33,204 33,275 33,350 33,360 33,393 33,422 33,491 33,497 33,463 NonMed_NonDrug \$179.38 \$264.65 \$196.24 \$213.57 \$198.48 \$210.00 \$210.92 \$219.18 \$240.92 \$197.54 \$224.33 \$218.01 \$82.11 \$138.21 \$123.33 \$128.20 \$123.34 \$128.20 \$123.34 \$128.20 \$123.34 \$128.20 \$123.34 \$128.20 \$123.34 \$128.20 \$123.34 \$128.20 \$123.34 \$126.20 \$123.34 \$126.20 \$123.34 \$126.20 \$123.34 \$128.20 \$123.34 \$128.20 \$123.34 \$128.20 \$123.34 \$128.20 \$123.34 \$128.50 \$123.34 \$128.50 \$123.34 \$128.50 \$12		,	,			,	,	,	,	,			
Jul-05 Aug-05 Sep-05 Oct-05 Nov-05 Dec-05 Jan-06 Feb-06 Mar-06 Apr-06 May-06 Jun-06 NonMed_NonDrug 102.95 116.37 111.76 117.94 113.97 109.65 156.44 125.70 138.21 123.43 128.20 123.34 NonMed_Drug 48.48 95.14 94.71 98.01 101.17 106.05 156.44 125.70 138.21 123.43 128.20 123.34 Med_Drug 48.48 95.14 94.71 98.01 101.17 106.05 156.41 125.70 138.21 123.43 128.20 123.34 Med_Drug 124.19 177.43 176.67 179.57 182.55 193.31 186.21 175.04 188.01 181.77 202.84 204.50 Total \$455.00 \$655.39 \$579.38 \$609.09 \$596.17 \$619.05 \$656.41 \$617.97 \$689.01 \$606.28 \$692.98 \$665.31 Change Fom Prior Year - Month to Month An	- •					,	,			,		,	,
NonMed_NonDrug \$179.38 \$264.65 \$196.24 \$213.57 \$198.48 \$210.00 \$210.92 \$219.18 \$240.92 \$197.54 \$246.33 \$218.03 Med_NonDrug 102.95 116.37 111.76 117.94 113.97 100.65 156.44 125.70 138.21 123.43 128.20 123.34 NonMed_Drug 48.48 95.14 94.71 98.01 101.17 106.08 102.84 98.06 111.87 103.54 115.61 119.44 Med_Drug 124.19 177.43 176.67 179.57 \$812.10 \$656.41 \$617.97 \$689.01 \$606.28 \$692.98 \$665.31 Change From Prior Year - Month to Month Analysis 1.4.3% -2.9% 1.5% -0.1% -4.3% 12.8% -14.7% Med_NonDrug 1.6% 42.3% 2.2% 18.3% 3.4% 14.3% -2.9% 1.5% -0.1% 4.3.5% 24.5% 32.7% NonMed_NonDrug 1.5% 31.2% 8.7% 7.4%	Med_Drug	32,020	32,901	33,007	33,204	33,275	33,300	33,300	33,393	33,4 22	33,491	33,497	33,403
Med_NonDrug 102.95 116.37 111.76 117.94 113.97 109.65 156.44 125.70 138.21 123.43 128.20 123.34 NonMed_Drug 48.48 95.14 94.71 98.01 101.17 106.08 102.84 98.06 111.87 103.54 115.61 119.44 Med_Drug 124.19 177.43 176.67 179.57 182.55 193.31 186.21 175.04 198.01 181.77 202.84 204.50 Total \$455.00 \$653.59 \$579.38 \$609.09 \$596.17 \$666.41 \$617.97 \$689.01 \$606.28 \$692.98 \$6665.31 NonMed_NonDrug 1.6% 42.3% 2.2% 18.3% 3.4% 14.3% -2.9% 1.5% -0.1% -4.3% 12.8% -14.7% Med_NonDrug 1.6% 42.3% 2.2% 18.3% 3.4% 14.3% -2.9% 1.5% -0.1% -4.3% 12.8% -14.7% MonMed_NonDrug 1.5% 11.4% 9.5% 7.4% 9.2% 0.2% 5.0% 1.2% 24.5%													
NonMed_Drug 48.48 95.14 94.71 98.01 101.17 106.08 102.84 98.06 111.87 103.54 115.61 119.44 Med_Drug 124.19 177.43 176.67 179.57 182.55 193.31 186.21 175.04 198.01 181.77 202.84 204.50 Total \$455.00 \$653.59 \$579.38 \$609.09 \$596.17 \$619.05 \$656.41 \$617.97 \$689.01 \$666.28 \$692.98 \$665.31 Change From Prior Year - Month to Month Analysis <th></th> <td>-</td> <td></td> <td></td> <td>-</td> <td>-</td> <td>-</td> <td></td> <td>-</td> <td></td> <td></td> <td>-</td> <td>-</td>		-			-	-	-		-			-	-
Med_Drug 124.19 177.43 176.67 179.57 182.55 193.31 186.21 175.04 198.01 181.77 202.84 204.50 Total \$455.00 \$653.59 \$579.38 \$609.09 \$596.17 \$619.05 \$656.41 \$617.97 \$689.01 \$606.28 \$692.98 \$665.31 Change From Prior Year - Month to Month Analysis NonMed_NonDrug 1.6% 42.3% 2.2% 18.3% 3.4% 14.3% -2.9% 1.5% -0.1% -4.3% 12.8% -14.7% Med_NonDrug 1.6% 42.3% 2.2% 18.3% 3.4% 14.3% -2.9% 1.5% -0.1% -4.3% 12.8% -14.7% Med_Drug 1.6% 42.3% 2.2% 18.3% 3.4% 14.3% -2.9% 1.5% -0.1% 24.5% 32.7% 2.7% NonMed_Drug -0.3% 23.6% -2.4% 31.2% 8.7% 3.3% 9.7% 11.0% 9.0% 4.4% 12.7% 9.3% 13.1% <td< td=""><th></th><td></td><td></td><td></td><td></td><td>113.97</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>						113.97							
Total \$455.00 \$653.59 \$579.38 \$609.09 \$596.17 \$619.05 \$656.41 \$617.97 \$689.01 \$606.28 \$692.98 \$665.31 Change From Prior Year - Month to Month Analysis NonMed_NonDrug 1.6% 42.3% 2.2% 18.3% 3.4% 14.3% -2.9% 1.5% -0.1% -4.3% 12.8% -14.7% Med_NonDrug 1.7% 9.4% 4.5% 11.4% 9.5% 7.4% 9.2% 0.2% 5.0% 1.2% 5.7% 2.7% NonMed_Drug -30.9% 23.4% 0.0% 37.3% 11.3% 3.9% 9.5% 11.5% 42.4% 43.5% 24.5% 32.7% Med_Drug 15.5% 23.6% -2.4% 31.2% 8.7% 3.3% 9.7% 11.0% 9.0% 4.4% 12.7% 9.3% Total -0.1% 27.4% 0.8% 23.2% 7.4% 7.6% 5.2% 5.3% 8.8% 5.5% 13.1% 1.9% NonMed_NonDrug 15.5%	- •												
Change From Prior Year - Month to Month Analysis NonMed_NonDrug 1.6% 42.3% 2.2% 18.3% 3.4% 14.3% -2.9% 1.5% -0.1% -4.3% 12.8% -14.7% Med_NonDrug 1.7% 9.4% 4.5% 11.4% 9.5% 7.4% 9.2% 0.2% 5.0% 1.2% 5.7% 2.7% NonMed_Drug -30.9% 23.4% 0.0% 37.3% 11.3% 3.9% 9.5% 11.5% 42.4% 43.5% 24.5% 32.7% Med_Drug -30.9% 23.6% -2.4% 31.2% 8.7% 7.3% 11.3% 3.9% 9.5% 11.5% 42.4% 43.5% 24.5% 32.7% Total -0.1% 27.4% 0.8% 23.2% 7.4% 7.6% 5.2% 5.3% 8.8% 5.5% 13.1% 1.9% Change From Prior Year - Quarter to Quarter Analysis 11.8% -0.5% 5.3% 8.8% 5.5% 13.1% 1.9% NonMed_Drug 1.5%	Med_Drug												
NonMed_NonDrug 1.6% 42.3% 2.2% 18.3% 3.4% 14.3% -2.9% 1.5% -0.1% -4.3% 12.8% -14.7% Med_NonDrug 1.7% 9.4% 4.5% 11.4% 9.5% 7.4% 9.2% 0.2% 5.0% 1.2% 5.7% 2.7% NonMed_Drug -30.9% 23.4% 0.0% 37.3% 11.3% 3.9% 9.5% 11.5% 42.4% 43.5% 24.5% 32.7% Med_Drug 15.5% 23.6% -2.4% 31.2% 8.7% 3.3% 9.7% 11.0% 9.0% 4.4% 12.7% 9.3% Total -0.1% 27.4% 0.8% 23.2% 7.4% 7.6% 5.2% 5.3% 8.8% 5.5% 13.1% 1.9% Change From Prior Year - Quarter to Quarter Analysis 11.8% -0.5% 5.0% 2.27% 2.4% 0.5% 5.0% 3.2% 0.5% 3.2% 0.5% 3.2% 0.5% 0.5% 3.2% 0.5% 0.5%	Total	\$455.00	\$653.59	\$579.38	\$609.09	\$596.17	\$619.05	\$656.41	\$617.97	\$689.01	\$606.28	\$692.98	\$665.31
Med_NonDrug 1.7% 9.4% 4.5% 11.4% 9.5% 7.4% 9.2% 0.2% 5.0% 1.2% 5.7% 2.7% NonMed_Drug -30.9% 23.4% 0.0% 37.3% 11.3% 3.9% 9.5% 11.5% 42.4% 43.5% 24.5% 32.7% Med_Drug 15.5% 23.6% -2.4% 31.2% 8.7% 3.3% 9.7% 11.0% 9.0% 4.4% 12.7% 9.3% Total -0.1% 27.4% 0.8% 23.2% 7.4% 7.6% 5.2% 5.3% 8.8% 5.5% 13.1% 1.9% Change From Prior Year - Quarter to Quarter Analysis 11.8% -0.5% 5.5% 13.1% 1.9% NonMed_NonDrug 15.5% 11.8% -0.5% 5.0% 3.2% NonMed_Drug -1.5% 11.8% -0.5% 5.0% 3.2% Med_Drug 0.1% 1.2% 1.2% 3.2% 3.2% NonMed_Drug 0.4% 1.2.3% 12.3%<	-			•									
NonMed_Drug -30.9% 23.4% 0.0% 37.3% 11.3% 3.9% 9.5% 11.5% 42.4% 43.5% 24.5% 32.7% Med_Drug 15.5% 23.6% -2.4% 31.2% 8.7% 3.3% 9.7% 11.0% 9.0% 4.4% 12.7% 9.3% Total -0.1% 27.4% 0.8% 23.2% 7.4% 7.6% 5.2% 5.3% 8.8% 5.5% 13.1% 1.9% Change From Prior Year - Quarter to Quarter Analysis -0.5% -2.7% -2.7% Med_NonDrug 15.5% 11.8% -0.5% 5.0% 32.2% NonMed_Drug 5.3% 9.5% 5.0% 32.2% NonMed_Drug 15.5% 11.8% -0.5% -2.7% Med_Drug 10.7% 15.5% 20.1% 32.8% NonMed_Drug 9.4% 12.3% 6.5% 6.5% 6.8% Change From Prior Year - Year to Year Analysis 12.3% 6.9% 6.7% <t< td=""><th>NonMed_NonDrug</th><td>1.6%</td><td>42.3%</td><td>2.2%</td><td>18.3%</td><td>3.4%</td><td>14.3%</td><td>-2.9%</td><td>1.5%</td><td>-0.1%</td><td>-4.3%</td><td>12.8%</td><td>-14.7%</td></t<>	NonMed_NonDrug	1.6%	42.3%	2.2%	18.3%	3.4%	14.3%	-2.9%	1.5%	-0.1%	-4.3%	12.8%	-14.7%
Med_Drug 15.5% 23.6% -2.4% 31.2% 8.7% 3.3% 9.7% 11.0% 9.0% 4.4% 12.7% 9.3% Total -0.1% 27.4% 0.8% 23.2% 7.4% 7.6% 5.2% 5.3% 8.8% 5.5% 13.1% 1.9% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug 15.5% 11.8% -0.5% 5.0% 3.2% NonMed_NonDrug 5.3% 9.5% 5.0% 3.2% 3.2% NonMed_Drug 1.5% 11.8% -0.5% -2.7% Med_Orug 1.5% 12.9% 9.9% 32.8% NonMed_Drug -1.5% 12.3% 6.5% 6.8% Change From Prior Year - Year to Year Analysis 12.3% 6.5% 6.8% Change From Prior Year - Year to Year Analysis 5.7% 6.9% 6.7% 5.3% NonMed_NonDrug 5.7% 6.9% 6.7% 5.6% 5.6% NonMed_NonDrug 5.7% 6.9% 6.7% 5.6%	Med_NonDrug	1.7%	9.4%	4.5%	11.4%	9.5%	7.4%	9.2%	0.2%	5.0%	1.2%	5.7%	2.7%
Total -0.1% 27.4% 0.8% 23.2% 7.4% 7.6% 5.2% 5.3% 8.8% 5.5% 13.1% 1.9% Change From Prior Year - Quarter to Quarter Analysis 11.8% -0.5% 5.3% 8.8% 5.5% 13.1% 1.9% NonMed_NonDrug 15.5% 11.8% -0.5% 5.0% 3.2% NonMed_NonDrug 5.3% 9.5% 5.0% 3.2% NonMed_Drug -1.5% 15.5% 20.1% 32.8% Med_Drug -1.5% 12.9% 9.9% 8.8% Total 9.4% 12.3% 6.5% 6.8% Change From Prior Year - Year to Year Analysis NonMed_NonDrug 1.4% 9.0% 8.7% 5.3% NonMed_NonDrug 1.4% 9.0% 8.7% 5.3% 5.6% NonMed_NonDrug 5.7% 6.9% 6.7% 5.3% Med_NonDrug 5.7% 6.9% 6.7% 5.6% NonMed_Drug 2.3% 4.8% 9.7% 17.0%	NonMed_Drug	-30.9%	23.4%	0.0%	37.3%	11.3%	3.9%	9.5%	11.5%	42.4%	43.5%	24.5%	32.7%
Change From Prior Year - Quarter to Quarter Analysis -0.5% -2.7% NonMed_NonDrug 15.5% 11.8% -0.5% -2.7% Med_NonDrug 5.3% 9.5% 5.0% 3.2% NonMed_Drug -1.5% 15.5% 20.1% 32.8% Med_Drug -1.5% 12.9% 9.9% 8.8% Total 9.4% 12.3% 6.5% 6.8% Change From Prior Year - Year to Year Analysis 9.0% 8.7% 5.3% NonMed_NonDrug 1.4% 9.0% 8.7% 5.3% Med_NonDrug 5.7% 6.9% 6.7% 5.6% NonMed_Drug 5.7% 4.8% 9.7% 17.0% Med_Drug 12.3% 16.6% 16.7% 10.5%	Med_Drug	<u>15.5%</u>	<u>23.6%</u>	<u>-2.4%</u>	<u>31.2%</u>	<u>8.7%</u>	<u>3.3%</u>	<u>9.7%</u>	<u>11.0%</u>	<u>9.0%</u>	<u>4.4%</u>	<u>12.7%</u>	<u>9.3%</u>
NonMed_NonDrug 15.5% 11.8% -0.5% -2.7% Med_NonDrug 5.3% 9.5% 5.0% 3.2% NonMed_Drug -1.5% 15.5% 20.1% 32.8% Med_Drug -1.5% 15.5% 20.1% 32.8% Med_Drug 10.7% 12.9% 9.9% 8.8% Total 9.4% 12.3% 6.5% 6.8% Change From Prior Year - Year to Year Analysis 7 7 7 NonMed_NonDrug 1.4% 9.0% 8.7% 5.3% Med_NonDrug 5.7% 6.9% 6.7% 5.6% NonMed_Drug -2.3% 4.8% 9.7% 17.0% Med_Drug 12.3% 16.6% 10.5% 10.5%	Total	-0.1%	27.4%	0.8%	23.2%	7.4%	7.6%	5.2%	5.3%	8.8%	5.5%	13.1%	1.9%
Med_NonDrug 5.3% 9.5% 5.0% 3.2% NonMed_Drug -1.5% 15.5% 20.1% 32.8% Med_Drug 10.7% 12.9% 9.9% 8.8% Total 9.4% 12.3% 6.5% 6.8% Change From Prior Year - Year to Year Analysis 7 6.5% 5.3% NonMed_NonDrug 1.4% 9.0% 8.7% 5.3% Med_NonDrug 5.7% 6.9% 6.7% 5.6% NonMed_Drug 2.3% 4.8% 9.7% 17.0% Med_Drug 12.3% 16.6% 16.7% 10.5%	Change From Prior	Year - Quart	ter to Quart	er Analysis	5								
NonMed_Drug -1.5% 15.5% 20.1% 32.8% Med_Drug 10.7% 12.9% 9.9% 8.8% Total 9.4% 12.3% 6.5% 6.8% Change From Prior Year - Year to Year Analysis 7 6.5% 5.3% NonMed_NonDrug 1.4% 9.0% 8.7% 5.3% Med_NonDrug 5.7% 6.9% 6.7% 5.6% NonMed_Drug -2.3% 4.8% 9.7% 17.0% Med_Drug 12.3% 16.6% 16.7% 10.5%	NonMed_NonDrug			15.5%			11.8%			-0.5%			-2.7%
Med_Drug 10.7% 12.9% 9.9% 8.8% Total 9.4% 12.3% 6.5% 6.8% Change From Prior Year - Year to Year Analysis 9.0% 8.7% 5.3% NonMed_NonDrug 1.4% 9.0% 8.7% 5.3% Med_NonDrug 5.7% 6.9% 6.7% 5.6% NonMed_Drug -2.3% 4.8% 9.7% 17.0% Med_Drug 12.3% 16.6% 16.7% 10.5%	Med_NonDrug			5.3%			9.5%			5.0%			3.2%
Total 9.4% 12.3% 6.5% 6.8% Change From Prior Year - Year to Year Analysis 9.0% 8.7% 5.3% NonMed_NonDrug 1.4% 9.0% 8.7% 5.3% Med_NonDrug 5.7% 6.9% 6.7% 5.6% NonMed_Drug -2.3% 4.8% 9.7% 17.0% Med_Drug 12.3% 16.6% 16.7% 10.5%	NonMed_Drug			-1.5%			15.5%			20.1%			32.8%
Change From Prior Year - Year to Year Analysis 9.0% 8.7% 5.3% NonMed_NonDrug 1.4% 9.0% 6.7% 5.3% Med_NonDrug 5.7% 6.9% 6.7% 5.6% NonMed_Drug -2.3% 4.8% 9.7% 17.0% Med_Drug 12.3% 16.6% 10.5%	Med_Drug			<u>10.7%</u>			<u>12.9%</u>			<u>9.9%</u>			<u>8.8%</u>
NonMed_NonDrug 1.4% 9.0% 8.7% 5.3% Med_NonDrug 5.7% 6.9% 6.7% 5.6% NonMed_Drug -2.3% 4.8% 9.7% 17.0% Med_Drug 12.3% 16.6% 16.7% 10.5%	Total			9.4%			12.3%			6.5%			6.8%
Med_NonDrug 5.7% 6.9% 6.7% 5.6% NonMed_Drug -2.3% 4.8% 9.7% 17.0% Med_Drug 12.3% 16.6% 16.7% 10.5%	Change From Prior	Year - Year	to Year Ana	alysis									
Med_NonDrug 5.7% 6.9% 6.7% 5.6% NonMed_Drug -2.3% 4.8% 9.7% 17.0% Med_Drug 12.3% 16.6% 16.7% 10.5%	NonMed_NonDrug			1.4%			9.0%			8.7%			5.3%
NonMed_Drug -2.3% 4.8% 9.7% 17.0% Med_Drug 12.3% 16.6% 16.7% 10.5%				5.7%			6.9%			6.7%			5.6%
Med_Drug 12.3% 16.6% 16.7% 10.5%	-												
	Total			4.6%			10.0%			10.6%			8.6%

NonMed_NonDrug \$176.89 \$214.29 \$184.80 \$198.99 \$204.84 \$234.58 \$200.4 \$205.99 \$225.04 \$242.40 \$242.40 \$240.18 \$235.69 Med_NonDrug 109.92 123.06 115.40 124.37 118.01 123.78 167.43 126.36 143.68 133.45 136.22 128.27 NonMed_Drug 55.51 102.88 105.83 109.14 109.35 119.61 113.13 100.68 114.58 109.14 112.57 108.00 Med_Drug 100.00 191.66 185.30 197.32 \$262.47 \$609.30 \$73.91 \$615.51 \$609.120 \$684.24 \$696.15 \$607.18 \$61.51 \$667.1						Figeal V	2007						
Jul-06 Aug-06 Sep-06 Oct-06 Nov-06 Dec-06 Jan-07 Feb-07 Mar-07 Apr-07 May-07 Jun-07 May-07 Jun-07<	Exposuro					FISCAL TE	ar 2007						
NonMed_NonDrug 15,718 16,375 16,476 16,483 15,710 16,604 16,581 16,525 16,454 16,279 16,375 Med_NonDrug 32,311 32,405 32,483 32,493 32,556 30,649 32,675 32,685 32,697 32,644 32,642 32,847 NonMed_Drug 43,559 15,171 15,265 15,272 14,554 15,385 15,312 15,247 15,086 Med_Drug 33,633 33,734 33,816 33,827 33,894 31,890 34,021 34,034 34,046 33,988 33,984 34,196 Med_Drug 109,92 123,06 115,40 124,37 118,01 123,78 167,43 126,36 143,68 133,45 136,22 128,27 NonMed_Drug 109,020 191,66 185,30 197,32 194,26 212,32 203,11 182,47 207,19 292,52 207,18 226,47 Total \$442,33 \$631,89 \$591,32 \$629,82	Exposure	1.1.06	Aug. 06	Son 06	Oct 06	Nov 06		lan_07	Fab.07	Mar 07	Apr 07	May 07	lup 07
Med_NonDrug 32,311 32,405 32,483 32,493 32,556 30,649 32,675 32,685 32,697 32,644 32,642 32,847 NonMed_Drug 14,559 15,171 15,265 15,272 14,554 15,385 15,365 15,312 15,247 15,046 15,119 Med_Drug 33,633 33,734 33,816 33,827 33,894 31,890 34,021 34,034 34,046 33,988 33,984 34,196 NonMed_NonDrug \$176.89 \$214.29 \$184.80 \$198.99 \$204.84 \$234.58 \$250.04 \$225.04 \$242.10 \$242.70 \$247.18 \$235.69 Mond_Drug 109.92 123.06 115.40 124.37 118.01 123.78 167.43 126.36 143.68 133.45 136.22 128.27 NonMed_Drug 100.00 191.66 185.30 197.32 194.26 212.32 203.31 182.47 207.90 199.25 207.18 226.47 Total \$442.33	NonMed NonDrug												
NonMed_Drug 14,559 15,171 15,265 15,262 15,272 14,554 15,385 15,385 15,312 15,247 15,086 15,119 Med_Drug 33,633 33,734 33,816 33,827 33,894 31,890 34,021 34,034 34,046 33,988 33,984 34,196 NonMed_Drug \$176.89 \$214.29 \$184.80 \$198.99 \$204.84 \$233.66 \$20.99 \$225.04 \$224.00 \$244.018 \$235.69 Med_NonDrug 109.92 123.06 115.40 124.37 118.01 123.78 167.43 126.36 143.68 133.45 136.22 128.27 NonMed_Drug 100.00 191.66 185.30 197.32 194.26 121.32 203.31 182.47 207.90 199.25 207.14 128.27 Total \$442.33 \$631.89 \$591.32 \$629.82 \$626.47 \$690.30 \$733.91 \$615.51 \$691.20 \$684.24 \$696.15 \$698.43 Change From Prior		,	,	,	,	,		,		,	,		
Med_Drug 33,633 33,734 33,816 33,827 33,894 31,890 34,021 34,034 34,046 33,988 33,984 34,196 NonMed_NonDrug \$176.89 \$214.29 \$184.80 \$198.99 \$204.84 \$223.06 \$124.29 \$184.80 \$198.99 \$204.84 \$220.04 \$225.04 \$224.04 \$224.01 \$226.01 \$226.01 \$226.01 \$226.01 \$226.01 \$226.01 \$226.01 \$226.01 \$226.01 \$226.01 \$226.01 \$226.01 \$226.01 \$262.01 \$262.01 \$262.01 \$262.01 \$262.01 \$262.01 \$262.01 \$267.01 \$260.01<		,	,	,	,	,		,	,	,	,	,	,
Jul-06 Aug-06 Sep-06 Oct-06 Nov-06 Dec-06 Jan-07 Feb-07 Mar-07 Apr-07 May-07 Jun-97 NonMed_NonDrug 119.92 123.06 115.40 124.37 118.01 123.78 167.43 126.36 143.68 133.45 136.22 128.27 NonMed_Drug 55.51 102.88 105.83 109.14 109.35 119.61 113.13 100.68 114.58 109.14 112.57 108.00 Med_Drug 100.00 191.66 185.30 197.32 194.26 212.32 203.31 182.47 207.90 199.25 207.18 2684.24 \$696.15 \$698.43 Change From Prior Year - Month to Month Analysis NonMed_NonDrug -1.4% -19.0% -5.8% -6.8% 3.2% 11.7% 18.5% -6.0% -6.6% 22.7% -2.5% 8.1% Med_NonDrug -1.4% -19.0% -5.8% -6.8% 3.2% 11.7% 18.5% -6.0% -6.6% 22.7% -2.5% </td <th>_ •</th> <td>,</td> <td></td> <td></td> <td>,</td> <td></td> <td></td> <td></td> <td></td> <td>,</td> <td></td> <td></td> <td></td>	_ •	,			,					,			
NonMed_NonDrug \$176.89 \$214.29 \$184.80 \$198.99 \$204.84 \$234.58 \$200.4 \$205.99 \$225.04 \$242.40 \$242.40 \$240.18 \$235.69 Med_NonDrug 109.92 123.06 115.40 124.37 118.01 123.78 167.43 126.36 143.68 133.45 136.22 128.27 NonMed_Drug 55.51 102.88 105.83 109.14 109.35 119.61 113.13 100.68 114.58 109.14 112.57 108.00 Med_Drug 100.00 191.66 185.30 197.32 \$262.47 \$609.30 \$73.91 \$615.51 \$609.120 \$684.24 \$696.15 \$607.18 \$61.51 \$667.1	Med_Didg	33,033	33,734	33,010	33,027	33,094	31,090	34,021	34,034	34,040	33,900	33,904	34,190
Med_NonDrug 109.92 123.06 115.40 124.37 118.01 123.78 167.43 126.36 143.68 133.45 136.22 128.27 NonMed_Drug 55.51 102.88 105.83 109.14 109.35 119.61 113.13 100.68 114.58 109.14 112.57 108.00 Med_Drug 100.00 191.66 185.30 197.32 194.26 212.32 203.31 182.47 207.90 199.25 207.18 226.47 Total \$442.33 \$631.89 \$591.32 \$629.82 \$626.47 \$690.30 \$733.91 \$615.51 \$691.20 \$684.24 \$696.15 \$698.43 Change From Prior Year - Month to Month Analysis NonMed_NonDrug -14.9% -19.0% -5.8% -6.8% 3.2% 11.7% 18.5% -6.0% -6.6% 22.7% -2.5% 8.1% NonMed_Drug 14.5% 8.1% 11.7% 11.4% 8.1% 12.8% 10.0% 2.7% 2.4% 5.4% -2.6% -9.6% NonMed_Drug -19.5% 8.0% 4.9% 9.8% 9.2% </td <th></th> <td></td> <td><u>Jun-07</u></td>													<u>Jun-07</u>
NonMed_Drug 55.51 102.88 105.83 109.14 109.35 119.61 113.13 100.68 114.58 109.14 112.57 108.00 Med_Drug 100.00 191.66 185.30 197.32 194.26 212.32 203.31 182.47 207.90 199.25 207.18 226.47 Change From Prior Year - Month to Month Analysis NonMed_NonDrug -1.4% -19.0% -5.8% -6.8% 3.2% 11.7% 18.5% -6.0% -6.6% 22.7% -2.5% 8.1% Med_NonDrug -1.4% -19.0% -5.8% -6.8% 3.2% 11.7% 18.5% -6.0% -6.6% 22.7% -2.5% 8.1% Med_NonDrug -1.4% 11.7% 11.4% 8.1% 12.8% 10.0% 2.7% 2.4% 5.4% -2.6% 9.6% -2.6% 9.6% 2.1% 10.7% Total -2.8% -3.3% 2.1% 3.4% 5.1% 11.5% 11.8% -0.4% 0.3% 2.2% 4.2% </td <th>-</th> <td></td>	-												
Med_Drug 100.00 191.66 185.30 197.32 194.26 212.32 203.31 182.47 207.90 199.25 207.18 226.47 Total \$442.33 \$631.89 \$591.32 \$629.82 \$626.47 \$690.30 \$733.91 \$615.51 \$691.20 \$684.24 \$696.15 \$698.43 Change From Prior Year - Month to Month Analysis NonMed_NonDrug -1.4% -19.0% -5.8% -6.8% 3.2% 11.7% 18.5% -6.0% -6.6% 22.7% -2.5% 8.1% Med_NonDrug 6.8% 5.7% 3.3% 5.4% 3.5% 12.9% 7.0% 0.5% 4.0% 8.1% 4.0% NonMed_Drug 14.5% 8.1% 11.7% 11.4% 8.1% 12.8% 10.0% 2.7% 2.4% 5.4% -2.6% -9.6% Med_Drug -9.5% 8.0% 4.9% 9.2% 4.2% 5.0% 9.6% 2.1% 10.7% Total -2.8% -3.3% 2.1% 3.4%<	Med_NonDrug		123.06		124.37	118.01		167.43	126.36	143.68	133.45	136.22	128.27
Total \$442.33 \$631.89 \$591.32 \$629.82 \$662.47 \$690.30 \$733.91 \$615.51 \$691.20 \$684.24 \$696.15 \$698.43 Change From Prior Year - Month to Month Analysis NonMed_NonDrug -1.4% -19.0% -5.8% -6.8% 3.2% 11.7% 18.5% -6.0% -6.6% 22.7% -2.5% 8.1% Med_NonDrug 6.8% 5.7% 3.3% 5.4% 3.5% 12.9% 7.0% 0.5% 4.0% 8.1% 6.3% 4.0% NonMed_Drug 14.5% 8.1% 11.7% 11.4% 8.1% 12.8% 10.0% 2.7% 2.4% 5.4% -2.6% -9.6% Med_Drug -9.5% 8.0% 4.9% 9.9% 6.4% 9.8% 9.2% 4.2% 5.0% 9.6% 2.1% 10.7% Total -2.8% -3.3% 2.1% 3.4% 5.1% 11.5% 11.8% -0.4% 0.3% 12.9% 0.5% 6.1% 5.0% 6.1% 5.6%	NonMed_Drug	55.51	102.88	105.83	109.14	109.35	119.61	113.13		114.58	109.14	112.57	108.00
Change From Prior Year - Month to Month Analysis NonMed_NonDrug -1.4% -19.0% -5.8% -6.8% 3.2% 11.7% 18.5% -6.6% 22.7% -2.5% 8.1% Med_NonDrug 6.8% 5.7% 3.3% 5.4% 3.5% 12.9% 7.0% 0.5% 4.0% 8.1% 6.3% 4.0% NonMed_Drug 14.5% 8.1% 11.7% 11.4% 8.1% 12.8% 10.0% 2.7% 2.4% 5.4% -9.6% Med_Drug -19.5% 8.0% 4.9% 9.9% 6.4% 9.8% 9.2% 4.2% 5.0% 9.6% 2.1% 10.7% Total -2.8% -3.3% 2.1% 3.4% 5.1% 11.5% 11.8% -0.4% 0.3% 12.9% 0.5% 5.0% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug 1.5% 8.5% 6.2% 7.4% 6.1% 6.2% 7.4% 6.6% 6.6% 6.6% 6.6% 6.6% 6.6% 6.6%	Med_Drug	<u>100.00</u>	<u>191.66</u>	<u>185.30</u>	<u>197.32</u>	<u>194.26</u>	<u>212.32</u>	<u>203.31</u>	<u>182.47</u>	<u>207.90</u>	<u>199.25</u>	<u>207.18</u>	<u>226.47</u>
NonMed_NonDrug -1.4% -19.0% -5.8% -6.8% 3.2% 11.7% 18.5% -6.0% -6.6% 22.7% -2.5% 8.1% Med_NonDrug 6.8% 5.7% 3.3% 5.4% 3.5% 12.9% 7.0% 0.5% 4.0% 8.1% 6.3% 4.0% NonMed_Drug 14.5% 8.1% 11.7% 11.4% 8.1% 12.8% 10.0% 2.7% 2.4% 5.4% -2.6% -9.6% Med_Drug -19.5% 8.0% 4.9% 9.9% 6.4% 9.8% 9.2% 4.2% 5.0% 9.6% 2.1% 10.7% Total -2.8% -3.3% 2.1% 3.4% 5.1% 11.5% 11.8% -0.4% 0.3% 12.9% 0.5% 5.0% Change From Prior Year - Quarter to Quarter Analysis -10.0% 2.6% 1.5% 4.1% 6.1% 5.0% 9.6% 5.0% 5.6% 6.1% 0.3% 12.9% 0.5% 5.6% 6.1% 5.6% 6.1% 5.6% 6.1% 5.6% 6.1% 5.6% 6.1% 5.6% 5.6%	Total	\$442.33	\$631.89	\$591.32	\$629.82	\$626.47	\$690.30	\$733.91	\$615.51	\$691.20	\$684.24	\$696.15	\$698.43
Med_NonDrug 6.8% 5.7% 3.3% 5.4% 3.5% 12.9% 7.0% 0.5% 4.0% 8.1% 6.3% 4.0% NonMed_Drug 14.5% 8.1% 11.7% 11.4% 8.1% 12.8% 10.0% 2.7% 2.4% 5.4% -2.6% -9.6% Med_Drug -19.5% 8.0% 4.9% 9.9% 6.4% 9.8% 9.2% 4.2% 5.0% 9.6% 2.1% 10.7% Total -2.8% -3.3% 2.1% 3.4% 5.1% 11.5% 11.8% -0.4% 0.3% 12.9% 0.5% 5.0% Change From Prior Year - Quarter to Quarter Analysis 0.0% 2.6% 1.5% 8.5% 5.0% 6.1% 0.5% 5.0% 0.5% 5.0% 6.1% 0.5% 5.0% 6.1% 0.5% 5.0% 6.1% 0.5% 5.0% 6.1% 0.5% 5.0% 6.2% 7.2% 0.7% 6.2% 7.4% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6% 5.6%	-			Analysis									
NonMed_Drug 14.5% 8.1% 11.7% 11.4% 8.1% 12.8% 10.0% 2.7% 2.4% 5.4% -2.6% -9.6% Med_Drug -19.5% 8.0% 4.9% 9.9% 6.4% 9.8% 9.2% 4.2% 5.0% 9.6% 2.1% 10.7% Total -2.8% -3.3% 2.1% 3.4% 5.1% 11.5% 11.8% -0.4% 0.3% 12.9% 0.5% 5.0% Change From Prior Year - Quarter to Quarter Analysis V V 11.5% 11.8% -0.4% 0.3% 12.9% 0.5% 5.0% Change From Prior Year - Quarter to Quarter Analysis V 2.6% 1.5% 8.5% Med_NonDrug 5.2% 7.2% 7.2% 4.1% 6.1% NonMed_Drug 0.9% 10.8% 5.0% 5.0% 2.6% Med_Drug 0.3% 6.2% 7.4% 5.0% 5.0% 5.0% Med_Drug -0.3% 8.7% 6.2% 7.2% 0.7%	NonMed_NonDrug	-1.4%	-19.0%	-5.8%	-6.8%	3.2%	11.7%	18.5%	-6.0%	-6.6%	22.7%	-2.5%	8.1%
Med_Drug -19.5% 8.0% 4.9% 9.9% 6.4% 9.8% 9.2% 4.2% 5.0% 9.6% 2.1% 10.7% Total -2.8% -3.3% 2.1% 3.4% 5.1% 11.5% 11.8% -0.4% 0.3% 12.9% 0.5% 5.0% Change From Prior Year - Quarter to Quarter Analysis NonMed_NonDrug -10.0% 2.6% 1.5% 8.5% Med_NonDrug 5.2% 7.2% 4.1% 6.1% NonMed_Drug 10.9% 10.8% 5.0% 2.6% 7.2% Med_Drug 10.9% 10.8% 5.0% 7.2% 4.1% 6.1% NonMed_Drug 0.9% 8.7% 6.2% 7.4% 7.4% 7.4% Total -1.3% 6.7% 3.9% 5.8% 7.4% 7.4% Change From Prior Year - Year to Year Analysis -2.7% -2.2% 0.7% 6.7% 9.6% 9.6% 9.6% 9.6% 9.6% 9.6% 9.6% 9.6% 9.6% 9.6% </td <th>Med_NonDrug</th> <td>6.8%</td> <td>5.7%</td> <td>3.3%</td> <td>5.4%</td> <td>3.5%</td> <td>12.9%</td> <td>7.0%</td> <td>0.5%</td> <td>4.0%</td> <td>8.1%</td> <td>6.3%</td> <td>4.0%</td>	Med_NonDrug	6.8%	5.7%	3.3%	5.4%	3.5%	12.9%	7.0%	0.5%	4.0%	8.1%	6.3%	4.0%
Total -2.8% -3.3% 2.1% 3.4% 5.1% 11.5% 11.8% -0.4% 0.3% 12.9% 0.5% 5.0% Change From Prior Year - Quarter to Quarter Analysis 2.6% 11.8% -0.4% 0.3% 12.9% 0.5% 5.0% NonMed_NonDrug -10.0% 2.6% 1.5% 8.5% Med_NonDrug 5.2% 7.2% 4.1% 6.1% NonMed_Drug 10.9% 10.8% 5.0% -2.6% Med_Drug -0.3% 8.7% 6.2% 7.4% Total -1.3% 6.7% 3.9% 5.8% Change From Prior Year - Year to Year Analysis -2.7% -2.2% 0.7% Med_NonDrug -0.8% -2.7% -2.2% 0.7% Med_NonDrug 5.6% 5.1% 4.9% 5.6% NonMed_NonDrug 5.6% 5.1% 4.9% 5.6% NonMed_Drug 19.9% 18.4% 14.2% 5.5% Med_Drug 7.9% 7.0% 6.1%	NonMed_Drug	14.5%	8.1%	11.7%	11.4%	8.1%	12.8%	10.0%	2.7%	2.4%	5.4%	-2.6%	-9.6%
Change From Prior Year - Quarter to Quarter Analysis 1.5% 8.5% NonMed_NonDrug -10.0% 2.6% 1.5% 8.5% Med_NonDrug 5.2% 7.2% 4.1% 6.1% NonMed_Drug 10.9% 10.8% 5.0% -2.6% Med_Drug -0.3% 8.7% 6.2% 7.4% Total -1.3% 6.7% 3.9% 5.8% Change From Prior Year - Year to Year Analysis 7.2% 0.7% NonMed_NonDrug -0.8% -2.7% -2.2% 0.7% Med_NonDrug 5.6% 5.1% 4.9% 5.6% NonMed_NonDrug 5.6% 5.1% 4.9% 5.6% Med_Drug 19.9% 18.4% 14.2% 5.5% Med_Drug 7.9% 7.0% 6.1% 5.7%	Med_Drug	<u>-19.5%</u>	<u>8.0%</u>	<u>4.9%</u>	<u>9.9%</u>	<u>6.4%</u>	<u>9.8%</u>	<u>9.2%</u>	<u>4.2%</u>	<u>5.0%</u>	<u>9.6%</u>	<u>2.1%</u>	<u>10.7%</u>
NonMed_NonDrug -10.0% 2.6% 1.5% 8.5% Med_NonDrug 5.2% 7.2% 4.1% 6.1% NonMed_Drug 10.9% 10.8% 5.0% -2.6% Med_Drug 10.9% 10.8% 5.0% -2.6% Med_Drug -0.3% 8.7% 6.2% 7.4% Total -1.3% 6.7% 3.9% 5.8% Change From Prior Year - Year to Year Analysis 6.7% 3.9% 5.8% NonMed_NonDrug -0.8% -2.7% -2.2% 0.7% Med_NonDrug 5.6% 5.1% 4.9% 5.6% NonMed_Drug 19.9% 18.4% 14.2% 5.5% Med_Drug 7.9% 7.0% 6.1% 5.7%	Total	-2.8%	-3.3%	2.1%	3.4%	5.1%	11.5%	11.8%	-0.4%	0.3%	12.9%	0.5%	5.0%
Med_NonDrug 5.2% 7.2% 4.1% 6.1% NonMed_Drug 10.9% 10.8% 5.0% -2.6% Med_Drug -0.3% 8.7% 6.2% 7.4% Med_Drug -0.3% 8.7% 6.2% 7.4% Total -1.3% 6.7% 3.9% 5.8% Change From Prior Year - Year to Year Analysis 0.7% 5.8% 5.8% NonMed_NonDrug -0.8% -2.7% -2.2% 0.7% Med_NonDrug 5.6% 5.1% 4.9% 5.6% NonMed_Drug 19.9% 18.4% 14.2% 5.5% Med_Drug 7.9% 7.0% 6.1% 5.7%	Change From Prior `	Year - Quart	ter to Quart	er Analysis									
NonMed_Drug 10.9% 10.8% 5.0% -2.6% Med_Drug -0.3% 8.7% 6.2% 7.4% Total -1.3% 6.7% 3.9% 5.8% Change From Prior Year - Year to Year Analysis 5.6% 5.1% 4.9% 5.6% NonMed_NonDrug -0.8% 5.1% 4.9% 5.6% NonMed_Drug 19.9% 18.4% 14.2% 5.5% Med_Drug 7.9% 7.0% 6.1% 5.7%	NonMed_NonDrug			-10.0%			2.6%			1.5%			8.5%
Med_Drug -0.3% 8.7% 6.2% 7.4% Total -1.3% 6.7% 3.9% 5.8% Change From Prior Year - Year to Year Analysis -0.8% -2.7% -2.2% 0.7% NonMed_NonDrug -0.8% 5.1% 4.9% 5.6% NonMed_Drug 19.9% 18.4% 14.2% 5.5% Med_Drug 7.9% 7.0% 6.1% 5.7%	Med_NonDrug			5.2%			7.2%			4.1%			6.1%
Total -1.3% 6.7% 3.9% 5.8% Change From Prior Year - Year to Year Analysis -1.3% 6.7% 3.9% 5.8% NonMed_NonDrug -0.8% -2.7% -2.2% 0.7% Med_NonDrug 5.6% 5.1% 4.9% 5.6% NonMed_Drug 19.9% 18.4% 14.2% 5.5% Med_Drug 7.9% 7.0% 6.1% 5.7%	NonMed_Drug			10.9%			10.8%			5.0%			-2.6%
Change From Prior Year - Year to Year Analysis -0.8% -2.7% -2.2% 0.7% NonMed_NonDrug -0.8% 5.1% 4.9% 5.6% Med_NonDrug 5.6% 5.1% 4.9% 5.6% NonMed_Drug 19.9% 18.4% 14.2% 5.5% Med_Drug <u>7.9%</u> <u>7.0%</u> <u>6.1%</u> 5.7%	Med_Drug			<u>-0.3%</u>			<u>8.7%</u>			<u>6.2%</u>			<u>7.4%</u>
NonMed_NonDrug -0.8% -2.7% -2.2% 0.7% Med_NonDrug 5.6% 5.1% 4.9% 5.6% NonMed_Drug 19.9% 18.4% 14.2% 5.5% Med_Drug 7.9% 7.0% 6.1% 5.7%	Total			-1.3%			6.7%			3.9%			5.8%
NonMed_NonDrug -0.8% -2.7% -2.2% 0.7% Med_NonDrug 5.6% 5.1% 4.9% 5.6% NonMed_Drug 19.9% 18.4% 14.2% 5.5% Med_Drug 7.9% 7.0% 6.1% 5.7%	Change From Prior	Year - Year	to Year Ana	alysis									
Med_NonDrug 5.6% 5.1% 4.9% 5.6% NonMed_Drug 19.9% 18.4% 14.2% 5.5% Med_Drug 7.9% 7.0% 6.1% 5.7%	NonMed_NonDrug			•			-2.7%			-2.2%			0.7%
NonMed_Drug 19.9% 18.4% 14.2% 5.5% Med_Drug 7.9% 7.0% 6.1% 5.7%	Med_NonDrug			5.6%			5.1%			4.9%			5.6%
Med_Drug 7.9% 7.0% 6.1% 5.7%	NonMed_Drug			19.9%			18.4%			14.2%			5.5%
	Med Drug												5.7%
	Total			6.0%			4.8%			4.1%			3.9%

					Fiscal Ye	or 2009						
Exposure					FISCAI I	ai 2000						
Exposure	<u>Jul-07</u>	Aug-07	Sep-07	Oct-07	<u>Nov-07</u>	Dec-07	Jan-08	Feb-08	Mar-08	Apr-08	May-08	Jun-08
NonMed_NonDrug	16,517	17,132	17,058	17,191	17,185	17,061	17,040	17,025	17,009	16,993	16,978	16,962
Med_NonDrug	1,062	1,123	1,185	1,247	1,308	1,370	1,432	1,493	1,555	1,617	1,678	1,740
NonMed Drug	15,304	15,874	15,805	15,928	15,920	15,807	15,785	15,770	15,755	15,740	15,725	15,711
Med_Drug	1,062	1,123	1,185	1,247	1,308	1,370	1,432	1,493	1,555	1,617	1,678	1,740
	Jul-07	Aug-07	Sep-07	Oct-07	Nov-07	<u>Dec-07</u>	Jan-08	Feb-08	Mar-08	<u>Apr-08</u>	May-08	Jun-08
NonMed_NonDrug	\$187.43	\$215.97	\$181.10	\$251.49	\$210.55	\$208.77	\$271.93	\$257.81	\$261.16	\$278.38	\$286.12	\$242.62
Med_NonDrug	11.53	18.41	19.67	27.77	42.34	51.34	79.46	91.13	106.04	99.58	73.25	73.61
NonMed Drug	66.79	94.84	71.57	81.00	98.28	97.62	110.65	101.86	105.63	104.50	104.93	101.30
Med_Drug	456.49	29.17	42.97	<u>33.56</u>	57.84	84.23	120.75	120.66	165.04	169.12	188.77	199.86
Total	\$722.24	\$358.39	\$315.32	\$393.82	\$409.01	\$441.96	\$582.79	\$571.45	\$637.87	\$651.58	\$653.07	\$617.38
Change From Prior	Year - Mont	h to Month	Analysis									
NonMed_NonDrug	6.0%	0.8%	-2.0%	26.4%	2.8%	-11.0%	8.8%	25.2%	16.1%	14.8%	19.1%	2.9%
Med_NonDrug	-89.5%	-85.0%	-83.0%	-77.7%	-64.1%	-58.5%	-52.5%	-27.9%	-26.2%	-25.4%	-46.2%	-42.6%
NonMed_Drug	20.3%	-7.8%	-32.4%	-25.8%	-10.1%	-18.4%	-2.2%	1.2%	-7.8%	-4.3%	-6.8%	-6.2%
Med_Drug	<u>356.5%</u>	<u>-84.8%</u>	<u>-76.8%</u>	<u>-83.0%</u>	<u>-70.2%</u>	<u>-60.3%</u>	<u>-40.6%</u>	<u>-33.9%</u>	<u>-20.6%</u>	<u>-15.1%</u>	<u>-8.9%</u>	<u>-11.7%</u>
Total	63.3%	-43.3%	-46.7%	-37.5%	-34.7%	-36.0%	-20.6%	-7.2%	-7.7%	-4.8%	-6.2%	-11.6%
Change From Prior	Year - Quart	ter to Quart										
NonMed_NonDrug			1.5%			5.1%			16.1%			12.4%
Med_NonDrug			-85.8%			-66.8%			-36.8%			-38.1%
NonMed_Drug			-11.7%			-18.1%			-3.1%			-5.8%
Med_Drug			<u>10.8%</u>			<u>-70.9%</u>			<u>-31.5%</u>			<u>-11.9%</u>
Total			-16.2%			-36.1%			-12.2%			-7.5%
Change From Prior	Year - Year	to Year Ana	alysis									
NonMed_NonDrug			3.6%			4.2%			8.1%			9.2%
Med_NonDrug			-15.8%			-33.3%			-44.6%			-55.2%
NonMed_Drug			0.7%			-6.8%			-8.8%			-9.6%
Med_Drug			<u>8.2%</u>			<u>-13.4%</u>			<u>-23.0%</u>			<u>-27.7%</u>
Total			0.6%			-10.3%			-14.5%			-17.8%